Yinghui Rong

Title: **Yinghui Rong: Pioneering Cancer Treatment Innovations**

Introduction

Yinghui Rong, an inventive scientist based in San Jose, CA, is recognized for his significant contributions to cancer treatment through innovative antibody therapies. He holds a patent that addresses one of the critical challenges in oncology: the effective treatment of various cancers associated with podocalyxin-like protein precursor isoform 2 (PODXL-v2).

Latest Patents

Rong's most notable patent is for the "Anti-PODXL antibody MAI1738 and its use for cancer treatment." This invention serves as a therapeutic agent for diagnosing, treating, and preventing various cancers that overexpress PODXL-v2. The applications of this patented invention are extensive, covering a wide range of cancers, including gastric cancers, glioblastoma, prostate cancer, and colorectal cancer. The innovative agent is based on the amino acid sequences of a novel monoclonal antibody (mAb), MAb1738, which has shown promise in inhibiting the proliferation of several human cancer cell lines and in controlling the growth and metastasis of gastric cancer in mouse models.

Career Highlights

Yinghui Rong is associated with Medabome, Inc., where he has been a key player in advancing cancer research. His work exemplifies the intersection of academic research and practical application, contributing significantly to therapeutic strategies for combatting complex diseases like cancer.

Collaborations

Rong collaborates with talented coworkers such as Mason Lu and Qinhong Ma. This collaboration fosters an environment of innovation, allowing for the exchange of ideas and furthering their collective research goals in cancer treatment.

Conclusion

Yinghui Rong's dedication to developing effective cancer therapies is evident through his patented work on anti-PODXL antibodies. His innovative approaches at Medabome, Inc., alongside his colleagues, underscore his pivotal role in advancing the field of oncology and improving patient outcomes in cancer treatment.